Subsequent Event	9 Months Ended
Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Event	Note 10 — Subsequent Event On November 1, 2024, we entered into the APA and certain other agreements (the Transactions) with an affiliate (the Purchaser) of Ampersand Capital Partners. Under the APA, the Purchaser will purchase our manufacturing facility located in Huntsville, Alabama (the Facility), and certain other related assets and will assume certain related liabilities, and we will assign our manufacturing and supply agreements for PEG reagents to the Purchaser. As consideration, we will receive $70 million in cash at closing of the Transactions (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser. The closing of the Transactions is subject to the satisfaction or waiver of certain customary closing conditions set forth in the APA. The APA contains customary representations and warranties of Nektar and Purchaser. Nektar has agreed to provide certain specific and customary indemnities to Purchaser for certain excluded liabilities not covered by a representation and warranties policy to be obtained by Purchaser in connection with the Transactions. In addition, the APA contains certain restrictive covenants, which will restrict, as of the closing of the Transactions, Nektar’s ability to manufacture and sell PEG reagents. In addition, the APA provides that, at the closing of the Transactions, each of Nektar and Purchaser will enter into certain ancillary agreements to effect the Transactions, including a mutual transition services agreement and a manufacturing and supply agreement and for Purchaser to supply to Nektar the PEG reagents for use in the manufacture of rezpegaldesleukin and NKTR-255.

Subsequent Event

9 Months Ended

Sep. 30, 2024

Note 10 — Subsequent Event

On November 1, 2024, we entered into the APA and certain other agreements (the Transactions) with an affiliate (the Purchaser) of Ampersand Capital Partners. Under the APA, the Purchaser will purchase our manufacturing facility located in

Huntsville, Alabama (the Facility), and certain other related assets and will assume certain related liabilities, and we will assign our manufacturing and supply agreements for PEG reagents to the Purchaser. As consideration, we will receive $70 million in cash at closing of the Transactions (subject to customary closing costs and adjustments based on closing net working capital, closing inventory and the amount of any indebtedness assumed by the Purchaser) and an approximate 20% equity ownership at the time of close in the Purchaser.

The closing of the Transactions is subject to the satisfaction or waiver of certain customary closing conditions set forth in the APA.

The APA contains customary representations and warranties of Nektar and Purchaser. Nektar has agreed to provide certain specific and customary indemnities to Purchaser for certain excluded liabilities not covered by a representation and warranties policy to be obtained by Purchaser in connection with the Transactions. In addition, the APA contains certain restrictive covenants, which will restrict, as of the closing of the Transactions, Nektar’s ability to manufacture and sell PEG reagents.

In addition, the APA provides that, at the closing of the Transactions, each of Nektar and Purchaser will enter into certain ancillary agreements to effect the Transactions, including a mutual transition services agreement and a manufacturing and supply agreement and for Purchaser to supply to Nektar the PEG reagents for use in the manufacture of rezpegaldesleukin and NKTR-255.